How Long Is ADT With Radiation for Prostate Cancer?

The duration of androgen-deprivation therapy (ADT) — often called hormone therapy — when combined with radiation depends primarily on the risk group of your prostate cancer. This information applies to men with localized (non-metastatic), generally node-negative prostate cancer who are receiving definitive radiation therapy.

For unfavorable-intermediate-risk prostate cancer, a short course of 4 to 6 months is typically recommended ^{[1] [2]}. For high-risk or very-high-risk prostate cancer, a longer course of 18 to 36 months is standard ^{[3] [4]}.

This timeframe is a major treatment decision that balances the goal of maximizing cancer control against the side effects of lowering your testosterone. Because every patient’s overall health and cancer is unique, these timeframes are guideline ranges, not automatic rules.

Understanding Your Risk Group and Typical Timelines

Your doctor assigns a risk group based on your PSA level, Grade Group (Gleason score), how much of the prostate is involved, and whether the cancer has spread.

Unfavorable-Intermediate Risk: Short-Course Therapy

If your cancer is classified as unfavorable-intermediate risk, radiation is usually combined with a “short course” of ADT lasting roughly 4 to 6 months ^{[1] [5]}.

Research shows that adding 4 to 6 months of hormone therapy to external-beam radiation reduces the risk of the cancer spreading and improves biochemical control (keeping PSA levels low) compared to using radiation alone ^{[2] [6]}. However, studies do not support extending the therapy to 18 or 36 months for this risk group, as the extra time on ADT has not been shown to provide enough added benefit to justify the prolonged side effects ^[1].

High and Very-High Risk: Long-Course Therapy

For high-risk and very-high-risk prostate cancer, a “long course” of ADT lasting 18 to 36 months is the standard recommendation ^{[3] [4]}.

Because high-risk cancer has a greater chance of having microscopic spread (tiny amounts of cancer outside the prostate), longer suppression of testosterone is used to help control these hormone-sensitive cancer cells. Clinical trials have shown that extending ADT beyond a 4-month course (up to 24 or 36 months) reduces the risk of metastasis and is associated with improved overall survival for men with high-risk disease ^{[7] [8]}.

While 2 to 3 years is standard, the exact length is often personalized through shared decision-making. A major trial comparing 18 months to 36 months did not find a statistically significant overall-survival difference, but the 18-month group reported a better quality of life ^[9]. Therefore, 18 months can be a reasonable option for appropriately selected men who want to limit their time on hormone therapy ^[9].

Understanding the Timing

Hormone therapy is usually wrapped around your radiation treatments in three phases ^[10]:

• Neoadjuvant (Before): ADT is often started before radiation (for example, 2 months prior, though timing varies). This reduces testosterone levels to help control the cancer and can shrink the prostate before radiation begins.
• Concurrent (During): You remain on ADT while actively receiving radiation treatments.
• Adjuvant (After): ADT continues after radiation finishes.

Clinical trials generally evaluated the total duration of the planned treatment rather than testing the exact length of each phase in isolation. The agreed-upon total duration is what matters most. Keep in mind that the “duration” refers to the time from your first dose to the end of the drug’s active window — and your body will need additional time (often months or longer) to recover testosterone production after the drug wears off.

Does a Brachytherapy Boost Change the Timeline?

Some men receive a brachytherapy boost — where internal radioactive material is temporarily or permanently placed in the prostate to deliver a higher, more focused radiation dose alongside external-beam radiation.

Because this combined radiation is so powerful, some researchers are studying whether it allows for a shorter course of ADT. Some observational data suggests a duration sometimes considered in selected patients with a boost might be closer to 12 to 18 months ^[11].

However, this is an evolving area of research. Randomized trials show mixed results, and getting a boost does not automatically mean a 6-month course will be equally effective as a longer course for high-risk disease ^{[12] [13]}. Any reduction in duration based on a brachytherapy boost changes both cancer-control evidence and side-effect considerations, and should be carefully discussed with your multidisciplinary team (your radiation, medical, and urologic oncologists).

Balancing Benefits and Side Effects

Choosing between maximizing cancer control and minimizing side effects can be emotionally difficult. ADT causes significant changes to the body, and its risks must be actively managed ^[14].

Common side effects include hot flashes, reduced libido, sexual dysfunction, fatigue, and weight gain ^[5]. Over longer periods, ADT can also cause muscle loss, insulin resistance (or worsening diabetes), lipid/cholesterol changes, mood effects, anemia, and loss of bone density (increasing fracture risk) ^{[5] [15] [16]}.

Safety and Monitoring:
Cardiovascular risk and metabolic changes should be assessed at baseline and monitored periodically (blood pressure, weight, glucose, lipids) ^[5]. You should also ask about a bone-density scan and discuss exercise/resistance training to preserve muscle and bone health ^[15].

Individualized Exceptions and Patient Safety

Your doctor will look at your overall health to decide if the standard timeline needs to be adjusted ^[1].

• Competing Health Risks: If you have severe pre-existing heart disease, serious metabolic issues, or other major health conditions, the risks of a long ADT course might outweigh the cancer-control benefits ^[17]. However, age or a cardiovascular condition does not automatically mean ADT should be omitted ^[18]. Your oncology and cardiology teams should work together to optimize your health and determine the safest plan.
• Managing Side Effects: Sometimes, patients start a 24-month course but experience severe side effects. Never stop, skip, or alter your ADT treatments on your own. If side effects become intolerable, contact your team promptly. They can often treat the side effects, change the medication, or have a documented discussion with you about the cancer-control trade-offs of stopping therapy early ^[18].

Glossary of Terms

• Disease-free survival: The length of time after treatment during which no sign of cancer is found.
• Metastasis: Cancer that has spread to a different part of the body.
• Neoadjuvant / Concurrent / Adjuvant: Treatments given before, during, and after the primary treatment (radiation), respectively.
• Osteopenia: Lower than normal bone density, which can lead to osteoporosis.
• Multidisciplinary team: A group of different types of medical specialists (like surgeons, medical oncologists, and radiation oncologists) who work together to plan a patient’s care.